Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KALA BIO, Inc. Director's Dealing 2021

Jun 21, 2021

35091_dirs_2021-06-21_858e3194-36ac-4034-b602-1bb60c847107.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2021-06-17

Reporting Person: Grunberg Gregory (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-17 Common Stock A 20000 Acquired 40000 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2534854 Indirect
Common Stock 2877006 Indirect

Footnotes

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

F2: Includes 20,000 unvested RSUs.

F3: Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of Longitude Venture Partners IV, L.P. ("LVP IV") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP IV and may be deemed to share voting and investment power over the securities held by LVP IV. The Reporting Person is a member of LCP IV and may be deemed to share voting and investment power over the securities of the issuer held by LVP IV. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F4: Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the securities of the issuer held by LVP II. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.